Bradanicline (INN,[1] code name TC-5619) is a drug which was being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder.[2] Phase I clinical trials were completed successfully, and it was in phase II trials.[3]
Clinical data | |
---|---|
Other names | TC-5619 |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
UNII |
|
KEGG |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C22H23N3O2 |
Molar mass | 361.445 g·mol−1 |
3D model (JSmol) |
|
| |
(verify) |
In May 2011, AstraZeneca declined to exercise its right to license the compound.[4] In September 2012, Targacept ended its development of badanicline for the purpose of treating ADHD in adults.[5] It was being studied for cognitive and memory enhancement.[6]
Bradanicline was discontinued for Alzheimer's disease and cognitive impairment in schizophrenia in late-2013.[7] It was also discontinued for ADHD.[7]